Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2021 Sep. 30 [cited 2024 Apr. 28];38(3):e2021035. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/11684